HPS Pharmacies wish to advise that Pfizer is experiencing a supply interruption for Dantrium® vials as follows:
Dantrium® Vials
Dantrolene sodium hemiheptahydrate 20mg
ARTG 14435
Normal supplies are expected to resume by the end of February 2026.
An internationally registered alternative of dantrolene 20mg vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Stock may also be accessed via the Special Access Scheme (SAS), if required. The estimated lead time for these products is 15 days.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates